Focused On-demand Library for BAI1-associated protein 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Brain-specific angiogenesis inhibitor I-associated protein 3

Alternative UPACC:

O94812; A2A2B2; B2RCD7; B4DGS5; B4DIK3; B4DRK9; B4DRP1; E7EUB9; H3BUH8; H3BVI3; H7C2Q1; O94839; Q2M226; Q658J2; Q76N05; Q96RZ3; Q9UJK1


BAI1-associated protein 3, also known as Brain-specific angiogenesis inhibitor I-associated protein 3, plays a crucial role in endosome to Golgi retrograde transport. It mediates endosome fusion with the trans-Golgi network in response to calcium influx, indirectly influencing dense-core secretory vesicle biogenesis and neurotransmitter and hormone secretion, including NPY, serotonin, and insulin.

Therapeutic significance:

Understanding the role of BAI1-associated protein 3 could open doors to potential therapeutic strategies by modulating neurotransmitter and hormone secretion, which may impact conditions related to neurotransmission and metabolic processes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.